Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 December Clinical practice Clinical study recommends against using antithrombotic therapy in ill outpatients with COVID-1... Read more
2022 November Pharma News FDA approval for brentuximab vedotin for children with high-risk Hodgkin lymphoma Read more
2022 November Pharma News FDA’s priority review to quizartinib for FLT-3 mutant AML patients Read more
2022 November Pharma News FDA’s decision on gene therapy Roctavian for adults with haemophilia A in early 2023 Read more
2022 November Clinical trials Encouraging results with loncastuximab tesirine plus rituximab for DLBCL patients Read more
Top
